A detailed history of Virtus Fund Advisers, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus Fund Advisers, LLC holds 1,294 shares of CPRX stock, worth $28,558. This represents 0.12% of its overall portfolio holdings.

Number of Shares
1,294
Previous 1,294 -0.0%
Holding current value
$28,558
Previous $20,000 25.0%
% of portfolio
0.12%
Previous 0.08%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.68 - $16.92 $3,904 - $4,500
266 Added 25.88%
1,294 $20,000
Q1 2023

May 15, 2023

BUY
$14.34 - $21.05 $14,741 - $21,639
1,028 New
1,028 $17,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.27B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Virtus Fund Advisers, LLC Portfolio

Follow Virtus Fund Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Fund Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus Fund Advisers, LLC with notifications on news.